A potential precision medicine approach for treating vision loss
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.
The study was published in Scientific Reports, and marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient’s tissue.
“Our vision is to develop a personalized approach to treating eye disease,” says Stephen Tsang, MD, PhD, the László Z. Bitó Associate Professor of Ophthalmology and associate professor of Pathology & Cell Biology at CUMC, ophthalmologist at NewYork-Presbyterian/Columbia, and one of the study’s senior authors. “We still have some way to go, but we believe that the first therapeutic use of CRISPR will be to treat an eye disease. Here we have demonstrated that the initial steps are feasible.”
In the study, the researchers created stem cells from a sample of skin that was taken from a patient with retinitis pigmentosa. As the patient-derived stem cells still harbored the disease-causing mutation, the teams used CRISPR to repair the defective gene. The stem cells can potentially be transformed into healthy retinal cells and transplanted back into the same patient to treat vision loss.
“The X-linked form of retinitis pigmentosa is an ideal candidate for a precision medicine approach because a common mutation accounts for 90% cases,” Tsang explains. Using CRISPR —which is easily adaptable to diverse sequences of DNA, and allows for fast and accurate editing —scientists can take a patient’s own cells and make pinpoint repairs specific to that individual’s genome.
Because the corrections are made in cells derived from the patient’s own tissue, doctors can re-transplant the cells with fewer fears of rejection by the immune system. Previous clinical trials have shown that generating retinal cells from embryonic stem cells and using them for transplantation is a safe and potentially effective procedure.
In this paper, the researchers targeted one of the most common variants of retinitis pigmentosa, which is caused by a single mistake in a gene called RGPR. The composition of RGPR—which contains many repeats and tight-binding nucleotide pairs—make it a difficult gene to edit. The researchers say that preliminary success with RGPR is therefore promising for treating other forms of the condition caused by mutations in other genes.
The current treatment for retinitis pigmentosa recommended by the National Institutes of Health—consuming high doses of vitamin A—slows down vision loss but does not cure the disease.
Other types of gene therapies for are currently undergoing clinical trials. Unlike CRISPR-based methods, these therapies introduce stretches of DNA that supplement some of the activity of the defective gene, but do not directly correct the original mutation. Follow-up studies have shown that any gains in vision from these gene supplementation therapies wane over time.
A CRISPR-driven precision medicine approach to treating retinitis pigmentosa may improve upon current therapies and restore a patient’s vision because CRISPR, with its pinpoint accuracy, can correct the fundamental genetic defect responsible for the disease. However, CRISPR technology has not yet been approved for use in humans.
The Latest on: Retinitis pigmentosa
[google_news title=”” keyword=”retinitis pigmentosa” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Retinitis pigmentosa
- Thomas Coysh, the 'Blind Skiwi' with an Olympic dreamon December 1, 2023 at 8:01 am
"When I’m out on the mountain, it’s me and my guides, skiing like anyone else does," says blind skier Thomas Coysh.
- Retinitis Pigmentosa News, Research and Latest Updateson November 26, 2023 at 4:01 pm
Keep abreast with the latest news related to Retinitis Pigmentosa there are 13 news items on Retinitis Pigmentosa that covers updates, breakthroughs and in-depth reports. We provide you with a ...
- Retinitis Pigmentosa: Genetics and Gene-Based Approaches to Therapyon November 24, 2023 at 4:00 pm
Significant advances have been made in the understanding of the genetics of retinitis pigmentosa (RP), a clinically and genetically heterogeneous group of disorders; and over 50 genes underlying ...
- Spanish ophthalmologist visits Holguin Retinitis Pigmentosa Centeron November 17, 2023 at 8:30 pm
Sergio Bonafonte Royo, specialist in Ophthalmology and director of the Bonafonte Ophthalmological Center of Spain, visited this Wednesday the Provincial Center of Retinitis Pigmentosa “Orfilio Pelaez” ...
- Risuteganib by Allegro Ophthalmics for Retinitis Pigmentosa (Retinitis): Likelihood of Approvalon November 14, 2023 at 4:00 pm
Risuteganib is under clinical development by Allegro Ophthalmics and currently in Phase I for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase I drugs for Retinitis Pigmentosa ...
via Bing News